A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics
The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Rationale The only systematic in vivo studies comparing antipsychotic (AP) effects on nucleus accumbens (NAc) shell and core dopamine (DA) transmission are voltammetric studies performed in pargyline-pretreated, halothane-anaesthetized rats. Studies in freely moving rats not pretreated with pargyline are not available. This study was intended to fill this gap by the use of in vivo microdialysis in freely moving rats.Methods Male Sprague-Dawley rats were implanted with microdialysis probes in the NAc shell and core and medial prefrontal cortex (PFCX). The next day, rats were administered intravenously with two or three doses of APs, and dialysate DA was monitored in 10-min samples. Some rats were pretreated with pargyline (75 mg/kg i.p.) and after 1 h were given clozapine or risperidone.Results Clozapine, risperidone, quetiapine, raclopride, sulpiride and amisulpride increased DA preferentially in the NAc shell. Such preferential effect on shell DA was not observed after haloperidol, chlorpromazine and olanzapine. In contrast to voltammetric studies, a preferential effect on NAc core DA was not observed after any dose of AP. Pargyline pretreatment did not reduce but actually amplified the preferential effect of clozapine and risperidone on NAc shell DA.Conclusions Apart from raclopride and olanzapine, the APs with lower extrapyramidal effects could be distinguished from typical APs on the basis of their ability to preferentially stimulate DA transmission in the NAc shell. There was no relationship between stimulation of PFCX DA and atypical APs profile. The differences between this study and voltammetry studies were not attributable to pargyline pretreatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“McLarnon et al [36] examined quetiapine misuse among clients from a community-based methadone maintenance program, and found that 80% of participants reported a lifetime quetiapine use; of these, 21% reported taking quetiapine exclusively without a prescription.”
Citations
Cites
1 retracted
Li, H.-Z., Guo, J., Gao, J., Han, L.-P., Jiang, C.-M., Li, H.-X., Bai, S.-Z., Zhang, W.-H., Li, G.-W., Wang, L.-N., et al. (2011) · Journal of Biomedical Science · doi:10.1186/1423-0127-18-18 · Cited by 97
RetractedThe Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963 · cited 4×
“…two dialysis probes aimed at the NAc shell on one side and at the NAc core or at the PFCX on the other side, according to the rat brain atlas of Paxinos and Watson (1998) (uncorrected coordinates: PFCX, anterior=+3.5, L=±0.6, from bregma; verti- cal=5.0 from dura; NAc shell, A=+2.0, L=0.9,…”
InfluentialThe rat brain in stereotaxic coordinates
Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,831
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 1×
“AP representative of different pharmacological categories were selected, namely haloperidol and chlorpromazine (high to intermediate D2R affinity and EPS liability), clozapine and quetiapine (low D2R, high to intermediate 5HT2A affinity and low EPS liability), amperozide (high 5HT2A, low D2R affinity and weak AP activ…”
Carlsson, A., & Lindqvist, M. (1963) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1963.tb01730.x · Cited by 2,148 · cited 1×
“Since the seminal studies by Carlsson (1974) (Carlsson and Lindqvist 1963), APs are known to increase all presynaptic indices of DA transmission, including synthesis, metabolism and release of DA and DA neuron firing activity (Anden et al.”
International Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301 · cited 2×
“individual doses of intramuscular and oral APs utilized in the clinic (Gardner et al. 2010).”
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140 · cited 4×
“In the case of clozapine and quetiapine, fast dissociation (koff) fromD2 receptors (Kapur and Seeman 2001) would allow the reduction of receptor occupancy in parallel with the decrease of brain drug concentrations due to its distribution to peripheral compartments.”
InfluentialWise, R. A. (1996) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(96)80079-1 · Cited by 1,072
Receptor activity and turnover of dopamine and noradrenaline after neuroleptics
Andén, N.-E., Butcher, S. G., Corrodi, H., Fuxe, K., & Ungerstedt, U. (1970) · European Journal of Pharmacology · doi:10.1016/0014-2999(70)90006-3 · Cited by 1,026 · cited 1×
“Since the seminal studies by Carlsson (1974) (Carlsson and Lindqvist 1963), APs are known to increase all presynaptic indices of DA transmission, including synthesis, metabolism and release of DA and DA neuron firing activity (Anden et al. 1970; Bunney 1988; Imperato and Di Chiara 1985).”
Nucleus accumbens shell and core dopamine: differential role in behavior and addiction
Di Chiara, G. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00286-3 · Cited by 996 · cited 1×
“, Gambro Hospal, Italy) by a modification of the method described by Tanda and Di Chiara (1998).”
Prefrontal Dopamine D1Receptors and Working Memory in Schizophrenia
Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D.-R., Keilp, J., Kochan, L., Van Heertum, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03708.2002 · Cited by 724 · cited 1×
“This property has been related to their low EPS liability and/or the ability to control negative symptoms (Abi-Dargham et al. 2002; Knable and Weinberger 1997).”
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715 · cited 2×
“In spite of the vast number of studies made in the attempt to identify a unitary mechanism for the lower extrapyramidal symptom (EPS) liability of clozapine and second-generation antipsychotics (APs), no consensus has been reached (AbiDargham and Laruelle 2005; Arnt and Skarsfeldt 1998; Ginovart and Kapur 2012; Meltze…”
Chiodo, L., & Bunney, B. (1983) · The Journal of Neuroscience · doi:10.1523/jneurosci.03-08-01607.1983 · Cited by 680 · cited 1×
“Selective depolarization inactivation of DA neurons to the shell with sparing of DA neurons projecting to the neostriatum has been proposed as the basis for the low EPS liability of clozapine and second-generation antipsychotics (Chiodo and Bunney 1983; Grace et al. 1997).”
Differential Effects of Classical and Atypical Antipsychotic Drugs on A9 and A10 Dopamine Neurons
White, F. J., & Wang, R. Y. (1983) · Science · doi:10.1126/science.6136093 · Cited by 588
Ichikawa, J., Ishii, H., Bonaccorso, S., Fowler, W. L., O'Laughlin, I. A., & Meltzer, H. Y. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00154.x · Cited by 494 · cited 1×
“This observation, in turn, is consistent with previous studies (Ichikawa et al. 1998, 2001; Imperato and Angelucci 1989; Kuroki et al. 1999; Moghaddam and Bunney 1990).”
Zahm, D. S. (2000) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00065-2 · Cited by 491 · cited 1×
“The NAc, however, is a heterogeneous area and has been distinguished into a ventromedial shell and a dorsolateral core that differ in terms of neurochemical composition, input and output connections, physiological and pharmacological responses and behavioural functions (Deutch and Cameron 1992; Di Chiara 2002; Heimer…”
Robertson, G. S., & Fibiger, H. C. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90054-6 · Cited by 474 · cited 1×
“Clozapine and most second-generation antipsychotics stimulate to a larger extent Fos-like immunoreactivity in the NAc shell than in the dorsolateral striatum and in the core, while the opposite applies to first-generation APs (Deutch et al. 1992; Dilts et al. 1993; Robertson and Fibiger 1992).”
Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell
Deutch, A. Y., & Cameron, D. S. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90007-o · Cited by 461 · cited 1×
“The NAc, however, is a heterogeneous area and has been distinguished into a ventromedial shell and a dorsolateral core that differ in terms of neurochemical composition, input and output connections, physiological and pharmacological responses and behavioural functions (Deutch and Cameron 1992; Di Chiara 2002; Heimer…”
The accumbens: beyond the core-shell dichotomy
(1997) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.9.3.354 · Cited by 415 · cited 1×
“The NAc, however, is a heterogeneous area and has been distinguished into a ventromedial shell and a dorsolateral core that differ in terms of neurochemical composition, input and output connections, physiological and pharmacological responses and behavioural functions (Deutch and Cameron 1992; Di Chiara 2002; Heimer…”
The Mechanism of Action of Novel Antipsychotic Drugs
Meltzer, H. Y. (1991) · Schizophrenia Bulletin · doi:10.1093/schbul/17.2.263 · Cited by 411 · cited 2×
“In spite of the vast number of studies made in the attempt to identify a unitary mechanism for the lower extrapyramidal symptom (EPS) liability of clozapine and second-generation antipsychotics (APs), no consensus has been reached (AbiDargham and Laruelle 2005; Arnt and Skarsfeldt 1998; Ginovart and Kapur 2012; Meltze…”
Moghaddam, B., & Bunney, B. S. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01230.x · Cited by 402 · cited 2×
“Another property of APs like clozapine, risperidone and olanzapine that block 5HT2A receptors is the ability to increase extracellular DA in the medial prefrontal cortex (PFCX) (Ichikawa et al. 1998, 2001; Imperato and Angelucci 1989; Kuroki et al. 1999; Moghaddam and Bunney 1990).”
Schoemaker, H., Claustre, Y., Fage, D., Rouquier, L., Chergui, K., Curet, O., Oblin, A., Gonon, F., Carter, C., Benavides, J., et al. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36395-5 · Cited by 371 · cited 2×
“Although amisulpride has been reported to preferentially stimulate DA metabolism in the NAc as compared to the caudateputamen, again no distinction has been made between shell and core (Schoemaker et al. 1997).”
Kuroki, T., Meltzer, H. Y., & Ichikawa, J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38019-x · Cited by 351 · cited 4×
“Another property of APs like clozapine, risperidone and olanzapine that block 5HT2A receptors is the ability to increase extracellular DA in the medial prefrontal cortex (PFCX) (Ichikawa et al. 1998, 2001; Imperato and Angelucci 1989; Kuroki et al. 1999; Moghaddam and Bunney 1990).”
InfluentialD2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons
Dragunow, M., Robertson, G. S., Faull, R. L. M., Robertson, H. A., & Jansen, K. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90399-o · Cited by 341
Imperato, A., & Di Chiara, G. (1985) · The Journal of Neuroscience · doi:10.1523/jneurosci.05-02-00297.1985 · Cited by 310
Robertson, G. S., Matsumura, H., & Fibiger, H. C. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23800-9 · Cited by 309 · cited 2×
“APs increase NAc shell Fos-like immunoreactivity and this effect has been related to their antipsychotic activity (Robertson et al. 1994).”
Antipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women With Schizophrenia?
O'Keane, V., & Meaney, A. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150223.31007.e0 · Cited by 307
Dopamine, the prefrontal cortex and schizophrenia
Knable, M. B., & Weinberger, D. R. (1997) · Journal of Psychopharmacology · doi:10.1177/026988119701100205 · Cited by 303 · cited 1×
“This property has been related to their low EPS liability and/or the ability to control negative symptoms (Abi-Dargham et al. 2002; Knable and Weinberger 1997).”
Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system
Andén, N.-E., & Stock, G. (1973) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1973.tb10025.x · Cited by 291 · cited 1×
“the ability of activating DA turnover preferentially in the nucleus accumbens (NAc) as compared to the dorsal striatum (Anden and Stock 1973; Bartholini 1976; White and Wang 1983).”
Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs
Grace, A. A., Bunney, B. S., Moore, H., & Todd, C. L. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10064-3 · Cited by 284 · cited 1×
“Selective depolarization inactivation of DA neurons to the shell with sparing of DA neurons projecting to the neostriatum has been proposed as the basis for the low EPS liability of clozapine and second-generation antipsychotics (Chiodo and Bunney 1983; Grace et al. 1997).”
Absorption, metabolism, and excretion of risperidone in humans.
Mannens, G., Huang, M. L., Meuldermans, W., Hendrickx, J., Woestenborghs, R., & Heykants, J. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08211-x · Cited by 261 · cited 2×
“…et al. 1996; Rosenzweig et al. 2002), or like risperidone, which is rapidly converted into the less liposoluble 9-hydroxy metabolite, paliperidone (Mannens et al. 1993; Muly et al. 2012), given in appropriate doses, increase DA preferentially in shell because the absence of the initial overshoot…”
Pharmacokinetics and Pharmacodynamics of Clozapine
Jann, M. W., Grimsley, S. R., Gray, E. C., & Chang, W.-H. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324020-00005 · Cited by 257 · cited 3×
“During the initial phase of drug distribution, whenmost of the drug is still in the blood, highly lipophilic APs, like clozapine, quetiapine, haloperidol and chlorpromazine, rapidly equilibrate with the highly perfused brain compartment (Balant-Gorgia and Balant 1987; Byerly and DeVane 1996; Jann et al. 1993; Javaid 1…”
Deutch, A. Y., Lee, M. C., & Iadarola, M. J. (1992) · Molecular and Cellular Neuroscience · doi:10.1016/1044-7431(92)90030-6 · Cited by 240 · cited 1×
“Clozapine and most second-generation antipsychotics stimulate to a larger extent Fos-like immunoreactivity in the NAc shell than in the dorsolateral striatum and in the core, while the opposite applies to first-generation APs (Deutch et al. 1992; Dilts et al. 1993; Robertson and Fibiger 1992).”
Tanda, G., & Di Chiara, G. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00135.x · Cited by 197
Self-citationAbi-Dargham, A., & Laruelle, M. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.11.003 · Cited by 179
Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia: D2-Occupancy Antipsychotic Drugs
Nord, M., & Farde, L. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00222.x · Cited by 177 · cited 3×
“During the initial phase of drug distribution, whenmost of the drug is still in the blood, highly lipophilic APs, like clozapine, quetiapine, haloperidol and chlorpromazine, rapidly equilibrate with the highly perfused brain compartment (Balant-Gorgia and Balant 1987; Byerly and DeVane 1996; Jann et al. 1993; Javaid 1…”
Bartholini, G. (1976) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1976.tb04648.x · Cited by 177 · cited 1×
“the ability of activating DA turnover preferentially in the nucleus accumbens (NAc) as compared to the dorsal striatum (Anden and Stock 1973; Bartholini 1976; White and Wang 1983).”
Rosenzweig, P., Canal, M., Patat, A., Bergougnan, L., Zieleniuk, I., & Bianchetti, G. (2002) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.320 · Cited by 177 · cited 3×
“Less lipophilic drugs like amisulpride and sulpiride, which slowly enter the brain (Mauri et al. 1996; Rosenzweig et al. 2002), or like risperidone, which is rapidly converted into the less liposoluble 9-hydroxy metabolite, paliperidone (Mannens et al.”
Serotonin, schizophrenia and antipsychotic drug action
Breier, A. (1995) · Schizophrenia Research · doi:10.1016/0920-9964(94)00043-8 · Cited by 174 · cited 1×
“Subsequent clinical experience, however, did cast doubt on its effectiveness as an antipsychotic , leading to interruption of its development (Breier 1995).”
Linnet, K., & Ejsing, T. B. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.06.003 · Cited by 163 · cited 1×
“P-glycoprotein) (Hartter et al. 2003; Linnet and Ejsing 2008).”
A model of anticholinergic activity of atypical antipsychotic medications
Chew, M. L., Mulsant, B. H., Pollock, B. G., Lehman, M. E., Greenspan, A. J., Kirshner, M. A., Bies, R. R., Kapur, S., & Gharabawi, G. M. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.011 · Cited by 151 · cited 2×
“instead to its powerful in vivo antimuscarinic properties, superimposable to those of clozapine (Bymaster et al. 2003; Chew et al. 2006).”
Muscarinic mechanisms of antipsychotic atypicality
Bymaster, F. P., Felder, C. C., Tzavara, E. T., Nomikos, G. G., Calligaro, D. O., & McKinzie, D. L. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.008 · Cited by 146
Liégeois, J.-F., Ichikawa, J., & Meltzer, H. Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02620-3 · Cited by 145 · cited 3×
“However, while Andersson et al. (1995) reported that ritanserin, a 5HT2A/2C antagonist, potentiates the DA stimulant properties of raclopride in the NAc, Liegeois et al. (2002) reported that ML100907, a selective 5HT2A antagonist, partially prevents the increase of dialysate DA induced by haloperidol in the NAc.”
InfluentialRole of Dopamine D2 Receptors for Antipsychotic Activity
Ginovart, N., & Kapur, S. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25761-2_2 · Cited by 141 · cited 1×
“In spite of the vast number of studies made in the attempt to identify a unitary mechanism for the lower extrapyramidal symptom (EPS) liability of clozapine and second-generation antipsychotics (APs), no consensus has been reached (AbiDargham and Laruelle 2005; Arnt and Skarsfeldt 1998; Ginovart and Kapur 2012; Meltze…”
Wu, Q., Reith, M. E. A., Kuhar, M. J., Carroll, F. I., & Garris, P. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-16-06338.2001 · Cited by 130 · cited 3×
“Due to this, changes in burst firing activity of DA neurons would induce larger changes in extracellular DA in the shell than in the core (Calipari et al. 2012; Jones et al. 1996; Wu et al. 2001).”
Nomikos, G. G., Iurlo, M., Andersson, J. L., Kimura, K., & Svensson, T. H. (1994) · Psychopharmacology · doi:10.1007/bf02244765 · Cited by 126 · cited 2×
“1999) but at variance with others (Ichikawa and Meltzer 1992, 2000; Marcus et al. 1996; Nomikos et al. 1994).”
Lecca, D., Cacciapaglia, F., Valentini, V., Grønli, J., Spiga, S., & Chiara, G. D. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0280-4 · Cited by 120 · cited 2×
“In order to perform intravenously (i.v.) drug administration, a catheter (Silastic, Dow Corning Corporation, Michigan, USA) was inserted in the right jugular vein according to the technique previously described (Lecca et al. 2006).”
Self-citationIchikawa, J., & Meltzer, H. Y. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02346-x · Cited by 118 · cited 1×
“…oral dose given to patients in the study by Axelsson et al. (1991), failed to increase DA in dialysates from the NAc shell, in agreement with some reports (Hertel et al. 1996; Kuroki et al. 1999) but at variance with others (Ichikawa and Meltzer 1992, 2000; Marcus et al. 1996; Nomikos et al. 1994).”
Jones, S. R., O'Dell, S. J., Marshall, J. F., & Wightman, R. M. (1996) · Synapse · doi:10.1002/(sici)1098-2396(199607)23:3<224::aid-syn12>3.0.co;2-z · Cited by 117
Hertel, P., Nomikos, G. G., Iurlo, M., & Svensson, T. H. (1996) · Psychopharmacology · doi:10.1007/bf02245607 · Cited by 110 · cited 2×
“…oral dose given to patients in the study by Axelsson et al. (1991), failed to increase DA in dialysates from the NAc shell, in agreement with some reports (Hertel et al. 1996; Kuroki et al. 1999) but at variance with others (Ichikawa and Meltzer 1992, 2000; Marcus et al. 1996; Nomikos et al. 1994).”
Pharmacokinetics of Clozapine and Risperidone: A Review of Recent Literature
Byerly, M. J., & DeVane, C. L. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00010 · Cited by 105 · cited 3×
“During the initial phase of drug distribution, whenmost of the drug is still in the blood, highly lipophilic APs, like clozapine, quetiapine, haloperidol and chlorpromazine, rapidly equilibrate with the highly perfused brain compartment (Balant-Gorgia and Balant 1987; Byerly and DeVane 1996; Jann et al. 1993; Javaid 1…”
Andersson, J. L., Nomikos, G. G., Marcus, M. M., Hertel, P., Mathé, J. M., & Svensson, T. H. (1995) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00172774 · Cited by 102 · cited 1×
“However, while Andersson et al. (1995) reported that ritanserin, a 5HT2A/2C antagonist, potentiates the DA stimulant properties of raclopride in the NAc, Liegeois et al. (2002) reported that ML100907, a selective 5HT2A antagonist, partially prevents the increase of dialysate DA induced by…”
Volonté, M., Monferini, E., Cerutti, M., Fodritto, F., & Borsini, F. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010182.x · Cited by 88
Ichikawa, J., Kuroki, T., Dai, J., & Meltzer, H. Y. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00308-2 · Cited by 88 · cited 1×
“This observation, in turn, is consistent with previous studies (Ichikawa et al. 1998, 2001; Imperato and Angelucci 1989; Kuroki et al. 1999; Moghaddam and Bunney 1990).”
Härnryd, C., Bjerkenstedt, L., Björk, K., Gullberg, B., Oxenstierna, G., Sedvall, G., Wiesel, F. ‐., Wik, G., & Åberg‐Wistedt, A. (1984) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1984.tb06856.x · Cited by 78
Antipsychotic drugs and catecholamine synapses
Carlsson, A. (1974) · Journal of Psychiatric Research · doi:10.1016/0022-3956(74)90070-3 · Cited by 77
Marcus, M. M., Nomikos, G. G., & Svensson, T. H. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)00056-u · Cited by 74 · cited 7×
“The higher dose level of clozapine and risperidone was taken from the study by Marcus et al. (1996) in order to compare the effect of these drugs in control and pargyline-pretreated rats.”
InfluentialA Risk-Benefit Assessment of Sulpiride in the Treatment of Schizophrenia
Mauri, M. C., Bravin, S., Bitetto, A., Rudelli, R., & INVERNIZZI, G. (1996) · Drug Safety · doi:10.2165/00002018-199614050-00003 · Cited by 74 · cited 4×
“Less lipophilic drugs like amisulpride and sulpiride, which slowly enter the brain (Mauri et al. 1996; Rosenzweig et al. 2002), or like risperidone, which is rapidly converted into the less liposoluble 9-hydroxy metabolite, paliperidone (Mannens et al.”
InfluentialCalipari, E. S., Huggins, K. N., Mathews, T. A., & Jones, S. R. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.07.008 · Cited by 73 · cited 3×
“Due to this, changes in burst firing activity of DA neurons would induce larger changes in extracellular DA in the shell than in the core (Calipari et al. 2012; Jones et al. 1996; Wu et al. 2001).”
Receptor binding properties of amperozide
Svartengren, J., & Simonsson, P. (1990) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1990.tb01599.x · Cited by 68 · cited 1×
“Amperozide is a weak D2 ligand but a strong 5HT2A receptor ligand (Svartengren and Simonsson 1990).”
Frånberg, O., Wiker, C., Marcus, M. M., Konradsson‐Geuken, Å., Jardemark, K. E., Schilström, B., Shahid, M., Wong, E. H. F., & Svensson, T. H. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0973-y · Cited by 68
Dilts, R. P., Helton, T. E., & McGinty, J. F. (1993) · Synapse · doi:10.1002/syn.890130308 · Cited by 63
Balant-Gorgia, A. E., & Balant, L. (1987) · Clinical Pharmacokinetics · doi:10.2165/00003088-198713020-00001 · Cited by 60 · cited 2×
“During the initial phase of drug distribution, whenmost of the drug is still in the blood, highly lipophilic APs, like clozapine, quetiapine, haloperidol and chlorpromazine, rapidly equilibrate with the highly perfused brain compartment (Balant-Gorgia and Balant 1987; Byerly and DeVane 1996; Jann et al. 1993; Javaid 1…”
Impérato, A., & Angelucci, L. (1989) · PubMed · Cited by 60
Effects of amperozide in schizophrenia
Axelsson, R., Nilsson, A., Christensson, E., & Björk, A. (1991) · Psychopharmacology · doi:10.1007/bf02246025 · Cited by 59
Ichikawa, J., & Meltzer, H. Y. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb10975.x · Cited by 56 · cited 1×
“…oral dose given to patients in the study by Axelsson et al. (1991), failed to increase DA in dialysates from the NAc shell, in agreement with some reports (Hertel et al. 1996; Kuroki et al. 1999) but at variance with others (Ichikawa and Meltzer 1992, 2000; Marcus et al. 1996; Nomikos et al. 1994).”
Narendran, R., Jedema, H. P., Lopresti, B. J., Mason, N. S., Gurnsey, K., Ruszkiewicz, J., Chen, C.-M., Deuitch, L., Frankle, W. G., & Bradberry, C. W. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.9 · Cited by 54
Clinical Pharmacokinetics of Antipsychotics
Javaid, J. I. (1994) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1994.tb01995.x · Cited by 50 · cited 3×
“During the initial phase of drug distribution, whenmost of the drug is still in the blood, highly lipophilic APs, like clozapine, quetiapine, haloperidol and chlorpromazine, rapidly equilibrate with the highly perfused brain compartment (Balant-Gorgia and Balant 1987; Byerly and DeVane 1996; Jann et al. 1993; Javaid 1…”
Garris, P. A., Carroll, F. I., Kuhar, M. J., Reith, M., & Wu, Q. (2000) · Journal of Neuroscience Nursing · Cited by 46
Härtter, S., Hüwel, S., Lohmann, T., el ela, A. A., Langguth, P., Hiemke, C., & Galla, H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300244 · Cited by 43 · cited 1×
“P-glycoprotein) (Hartter et al. 2003; Linnet and Ejsing 2008).”
Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial.
Gb, C., Castrogiovanni, P., Conti, L., & Bonollo, L. (1975) · PubMed · Cited by 43
Marcus, M. M., Nomikos, G. G., & Svensson, T. H. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00077-8 · Cited by 42 · cited 2×
“As far as the voltammetric studies by Marcus et al. (1996, 2000, 2002) are concerned, many discrepancies are found.”
Shilliam, C. S., & Dawson, L. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300591 · Cited by 36 · cited 2×
“This pattern of change has been interpreted as due to depolarization inactivation of ventrotegmental area neurons projecting to the shell (Shilliam and Dawson 2005).”
Adachi, Y., Yamada, S., Satomoto, M., Higuchi, H., Watanabe, K., Kazama, T., Mimuro, S., & Sato, S. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.07.012 · Cited by 35 · cited 2×
“…halothane anaesthesia has been reported to reduce the increase of striatal dialysate DA induced by haloperidol and to increase that elicited by clozapine (Adachi et al. 2003) while fluothane anaesthesia has been reported to attenuate the effect of clozapine and risperidone (Adachi et al. 2008).”
Effects of Acute and Chronic Neuroleptic Treatment on the Activity of Mid brain Dopamine Neuronsa
Bunney, B. S. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb42097.x · Cited by 27 · cited 1×
“Since the seminal studies by Carlsson (1974) (Carlsson and Lindqvist 1963), APs are known to increase all presynaptic indices of DA transmission, including synthesis, metabolism and release of DA and DA neuron firing activity (Anden et al. 1970; Bunney 1988; Imperato and Di Chiara 1985).”
Johnson, M. G., Kozielska, M., Reddy, V. P., Vermeulen, A., Li, C., Grimwood, S., de Greef, R., Groothuis, G. M. M., Danhof, M., & Proost, J. H. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0477-7 · Cited by 26 · cited 3×
“During the initial phase of drug distribution, whenmost of the drug is still in the blood, highly lipophilic APs, like clozapine, quetiapine, haloperidol and chlorpromazine, rapidly equilibrate with the highly perfused brain compartment (Balant-Gorgia and Balant 1987; Byerly and DeVane 1996; Jann et al. 1993; Javaid 1…”
Muly, E. C., Votaw, J. R., Ritchie, J., & Howell, L. L. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189076 · Cited by 26 · cited 2×
“…et al. 2002), or like risperidone, which is rapidly converted into the less liposoluble 9-hydroxy metabolite, paliperidone (Mannens et al. 1993; Muly et al. 2012), given in appropriate doses, increase DA preferentially in shell because the absence of the initial overshoot allows titration of…”
Morris, E. D., Normandin, M. D., & Schiffer, W. K. (2008) · Molecular Imaging and Biology · doi:10.1007/s11307-007-0124-1 · Cited by 24 · cited 1×
“Such a study might have predictive translational value, due to the high degree of concordance between microdialysis and PET as a means to monitor extracellular DA dynamics in specific brain areas (Morris et al. 2008; Narendran et al. 2014).”
Carboni, E. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00085-8 · Cited by 22 · cited 2×
“up to 300 % in the bed nucleus stria terminalis (Carboni et al. 2000).”
InfluentialPharmacokinetics of neuroleptics.
Verghese, C., Kessel, J. B., & Simpson, G. M. (1991) · PubMed · Cited by 21
Marcus, M. M., Malmerfelt, A., Nyberg, S., & Svensson, T. H. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00048-2 · Cited by 17
The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats
Wirtshafter, D., & Osborn, C. V. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.11.003 · Cited by 16 · cited 1×
“However, Fos activation in the dorsolateral striatum by typical APs is resistant to D1 blockade by SCH 23390 (Dragunow et al. 1990; Wirtshafter and Osborn 2005).”
Lomas, C. (2013) · Nursing Standard · doi:10.7748/ns2013.11.28.11.20.s25 · Cited by 15
Halothane attenuated haloperidol and enhanced clozapine-induced dopamine release in the rat striatum
Adachi, Y., Aramaki, Y., Satomoto, M., Higuchi, H., & Watanabe, K. (2003) · Neurochemistry International · doi:10.1016/s0197-0186(02)00227-9 · Cited by 13 · cited 2×
“…halothane anaesthesia has been reported to reduce the increase of striatal dialysate DA induced by haloperidol and to increase that elicited by clozapine (Adachi et al. 2003) while fluothane anaesthesia has been reported to attenuate the effect of clozapine and risperidone (Adachi et al. 2008).”
Csernansky, J. G., Newcomer, J. W., Jackson, K., Lombrozo, L., Faull, K. F., Zipursky, R. B., Adolf Pfefferbaum, A., & Faustman, W. O. (1994) · Psychopharmacology · doi:10.1007/bf02245331 · Cited by 10 · cited 1×
“AP representative of different pharmacological categories were selected, namely haloperidol and chlorpromazine (high to intermediate D2R affinity and EPS liability), clozapine and quetiapine (low D2R, high to intermediate 5HT2A affinity and low EPS liability), amperozide (high 5HT2A, low D2R affinity and weak AP activ…”
Rummel‐Kluge, C. (2010) · Evidence-Based Mental Health · doi:10.1136/ebmh.13.4.106 · Cited by 1 · cited 1×
“AP representative of different pharmacological categories were selected, namely haloperidol and chlorpromazine (high to intermediate D2R affinity and EPS liability), clozapine and quetiapine (low D2R, high to intermediate 5HT2A affinity and low EPS liability), amperozide (high 5HT2A, low D2R affinity and weak AP activ…”
Rummel‐Kluge, C. (2010) · Evidence-Based Mental Health · doi:10.1136/ebmh1096 · Cited by 1
Cited by
Schifano, F., Chiappini, S., Corkery, J., & Guirguis, A. (2018) · Brain Sciences · doi:10.3390/brainsci8040073 · Cited by 93
Amato, D., Vernon, A., & Papaleo, F. (2018) · Neuroscience and Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.09.027 · Cited by 79
Shin, J. H., Adrover, M. F., & Alvarez, V. A. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0596-17.2017 · Cited by 70
“M2/4 mAChRs in CIN terminals depress the electrically evoked DA transients by inhibiting the release of ACh (Threlfell et al., 2010; Shin et al., 2015), M5 in DAN terminals potentiates the release of DA (Shin et al., 2015), and M4 mAChRs in D1 medium spiny neurons depresses the release of DA…”
BackgroundAddiction theory matters—Why there is no dependence on caffeine or antidepressant medication
Heinz, A., Daedelow, L. S., Wackerhagen, C., & Di Chiara, G. (2020) · Addiction Biology · doi:10.1111/adb.12735 · Cited by 45
Chiappini, S., & Schifano, F. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000814 · Cited by 44
Metadata
- Authors
- Tanda, G., Valentini, V., De Luca, M. A., Perra, V., Serra, G. P., & Di Chiara, G.
- Affiliations
- University of Cagliari (IT)
- Venue
- Psychopharmacology
- Published
- 2014-10-28
- Volume
- 232
- Issue
- 8
- Pages
- 1427-1440
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2038445102
- Cited by
- 33
- References
- 86
- Citations by year
- 2026: 1 · 2024: 3 · 2022: 3 · 2021: 1 · 2020: 6 · 2019: 4 · 2018: 2 · 2017: 10 · 2016: 3
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Funders
- Ministero dell'Università e della Ricerca
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- antipsychotic drugs, dopamine signaling, nucleus accumbens shell, nucleus accumbens core, medial prefrontal cortex, clozapine, risperidone, quetiapine, raclopride, sulpiride, amisulpride, haloperidol, chlorpromazine, olanzapine, extrapyramidal symptoms, atypical antipsychotics, freely moving rats
- MeSH terms
- Animals, Chlorpromazine, Clozapine, Dopamine, Haloperidol, Male, Nucleus Accumbens, Time Factors, Antipsychotic Agents, Rats, Sprague-Dawley, Prefrontal Cortex, Microdialysis, Risperidone, Raclopride, Rats, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.